Systemic Lupus Erythematosus- Cartesian DC08-SLE-001

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).

Inclusion Criteria:

  • Patient must be at least 18 years of age.
  • Patient must have systemic lupus erythematosus (SLE) at the time of screening.
  • Active symptoms despite recent or ongoing immunosuppressive therapy with glucocorticoids and at least 2 other immunosuppressive medications being tried for at least 12 weeks within 24 months of screening.
  • At least one of: anti-dsDNA, anti-histone, anti-chromatin, and/or anti-Sm antibodies detectable at screening as assessed by a CLIA-certified laboratory.

Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

Locations

Arthritis Consultants of North County

3998 Vista Way
Suite E
Oceanside, California